# Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

> **NCT04022343** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 22 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v8

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT04022343
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-06
- **Primary completion:** 2022-02-02
- **Final completion:** 2026-12-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04022343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04022343, "Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04022343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*